Drug Profile


Alternative Names: CB 2562; CB 40067; CCRIS 2781; Dihydroxybusulphan; HSDB 6963; NSC 39069; Ovastat

Latest Information Update: 23 Oct 2015

Price : $50

At a glance

  • Originator Medac
  • Developer Center for International Blood and Marrow Transplant Research; Medac
  • Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Acute lymphoblastic leukaemia; Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders
  • No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2015 Medac completes a phase II trial in Acute Myeloid leukaemia and Myelodysplastic syndrome (in infants, children and adoloscents) in USA (NCT01772953)
  • 31 Mar 2015 Discontinued - Phase-II for Malignant melanoma in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top